Literature DB >> 10671323

New uses for new and old quinolones and the challenge of resistance.

D C Hooper1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10671323     DOI： 10.1086/313677

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  27 in total

1.  In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.

Authors:  M P Montanari; M Mingoia; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

2.  In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 3.  Development of novel antibacterial drugs to combat multiple resistant organisms.

Authors:  Matteo Bassetti; Elda Righi
Journal:  Langenbecks Arch Surg       Date:  2015-02-11       Impact factor: 3.445

4.  In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model.

Authors:  Yuichi Fukuda; Katsunori Yanagihara; Hideaki Ohno; Yasuhito Higashiyama; Yoshitsugu Miyazaki; Kazuhiro Tsukamoto; Yoichi Hirakata; Kazunori Tomono; Yohei Mizuta; Takayoshi Tashiro; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

5.  Oxidation of ofloxacin by Oxone/Co(2+): identification of reaction products and pathways.

Authors:  Yunqing Pi; Jinglan Feng; Jingyu Sun; Mengke Song; Jianhui Sun
Journal:  Environ Sci Pollut Res Int       Date:  2013-11-01       Impact factor: 4.223

6.  Fluoroquinolone antimicrobial drugs.

Authors:  Tiffany Chan; Paul E Bunce
Journal:  CMAJ       Date:  2017-05-01       Impact factor: 8.262

7.  Safety of fluoroquinolones: An update.

Authors:  L Mandell; G Tillotson
Journal:  Can J Infect Dis       Date:  2002-01

8.  Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia.

Authors:  Oliver A Cornely; Thomas Wicke; Harald Seifert; Ullrich Bethe; Martin Schwonzen; Dietmar Reichert; Andrew J Ullmann; Meinolf Karthaus; Kai Breuer; Bernd Salzberger; Volker Diehl; Gerd Fätkenheuer
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490

Review 9.  New developments in antibacterial choice for lower respiratory tract infections in elderly patients.

Authors:  Anna Maria Ferrara; Anna Maria Fietta
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 10.  Maintaining fluoroquinolone class efficacy: review of influencing factors.

Authors:  W Michael Scheld
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.